Endovascular Treatment Devices Market to See 7.3 Percent Annual Growth Through 2022

Increasing acceptance of endovascular procedures and increasing diagnosis of aortic aneurysms worldwide are two factors helping to drive the endovascular treatment devices market. The industry expects to see a compound annual growth rate (CAGR) of 7.3% through 2022, when it could be worth more than $2.8 billion, as outlined in the report Endovascular Treatment Devices: EVAR and TEVAR Emphasis. Major players in the market mentioned in this report include Altura Medical, BiFlow Medical, Boston Scientific, Cardinal Health, Endologix, Endospan, Getinge, InspireMD, Japan Lifeline, Lifetech Scientific, Lombard Medical Technologies, Medtronic, Nellix, Penumbra and Terumo.

Research Highlights

• By size, the market is led by the United States, with an estimated 2022 value of $1.5 billion, though by growth the market will be led by Asia, with a CAGR through the period of 8.4%.
• Companies leading the market in 2016 include Medtronic, W.L. Gore, Cook Medical and Endologix.
• Key marketed AAA products include the Dominus Stent Graft, LINUS Stent Graft, INCRAFT AAA Stent Graft System and the Self-Expandable Percutaneous Aortoiliac Stent Graft Endoprosthesis. Key pipeline products include the BiFlow Nitinol Stent, Zenith p-Branch, Zenith Dissection Endovascular Stent System and Ventana Fenestrated Stent Graft System.

“Endovascular treatment (e.g., EVAR, TEVAR) has created a great buzz in the last decade due to its advantages over open surgical repair,” said BCC Research analyst and report author Dr Ritu Thakur Dangi. “The US leads the market of both segments, followed by Europe, Asia and ROW. Although Asia is growing fast, the US will continue to have the largest share in the global aortic stent graft market through 2022. TAA is a relatively new and niche segment globally, but it is growing and has a strong growth potential for the future due to a strong pipeline of products from early-stage start-ups and established players.”

Growing Geriatric Population Expected to Drive Global Market

The worldwide increase in the geriatric population is helping to drive the market, the report adds, as elderly people are at a higher risk of acquiring various diseases. In the United States, average life expectancy will increase from 77.8 years in 2005 to 79.8 years in 2020, while in Europe the population 65 and older will increase at a CAGR of 1.6% between 2010 and 2030, from 121 million to 165 million. The story is similar in Japan, where the population age 65 and older will increase from 29 million in 2010 to 37 million by 2030. – BCC Research